MARQUETTE, Mich., Dec. 16 /PRNewswire/ -- Pioneer Surgical Technology, Inc., a leading innovator in the design and manufacture of spinal and orthopedic implants and instruments, today announced the closing of Series B financing totaling $15 million. Pioneer attracted new participation from InvestMichigan! Growth Capital Fund (IMGCF). Previous investors Pharos Capital Group, LLC; Highlander Partners, LP; Hopewell Ventures; and River Cities Capital Funds also participated in the round.
Pioneer's CEO and Chairman of the Board, Matthew N. Songer, MD, MBA says, "This capital will fund our FDA pivotal study for the NuBac nucleus replacement device, enabling us to bring this innovative P3(TM) technology to the U.S. market."
Pioneer is the first and only company to receive FDA approval to start the IDE pivotal study for lumbar nucleus replacement. The NuBac is a minimally-invasive device and is the first in a family of PEEK-on-PEEK articulating discs and implants developed by Pioneer.
IMGCF co-manager Charles Rothstein, of Beringea, Inc., commented, "With its focus on one of the largest, fastest growing and most profitable segments in the medical device industry, we feel confident Pioneer Surgical will be a valuable addition to the IMGCF portfolio."
The NuBac implant system is the only Nucleus Replacement device that utilizes an articulating inner ball and socket design that seeks to achieve load sharing and uniform stress distribution under various physiological loading conditions while minimizing extrusion risk. The NuBac implant is made of PEEK-OPTIMA(R) material which offers well established biocompatibility, biodurability, excellent wear resistance, and radiolucency.
San Francisco, California-based Thomas Weisel Partners served as sole financial advisor to Pioneer in connection with the Series B financing.
About Pioneer Surgical Technology
|SOURCE Pioneer Surgical Technology, Inc.|
Copyright©2008 PR Newswire.
All rights reserved